Last Updated : August 30, 2022
We recently experienced problems with its website hosting platform that prevented users from downloading documents from cda-amc.ca – including draft reimbursement recommendations and stakeholder feedback forms.
The issue has been resolved and all documents on our website are now accessible to everyone.
When the problem was identified, we contacted sponsors and patient groups and provided them with copies of the draft recommendations and feedback forms for the reimbursement reviews currently open for feedback. Sponsors also received the reconsideration forms.
Today, we are extending our stakeholder feedback deadlines as follows:
| Drug | Therapeutic Area | Revised Timelines for Stakeholder Feedback |
|---|---|---|
| Non-Oncology Drugs | ||
| lemborexant (Dayvigo) | Insomnia |
September 2, 2022: Deadline for sponsors to provide feedback or submit a request for reconsideration. |
| berotralstat (Orladeyo) | Hereditary angioedema | |
| semaglutide (Wegovy) | Weight management | |
| ruxolitinib (Jakavi) | Graft versus host disease | |
Eligible stakeholders who were not contacted by us can now access the draft recommendations and feedback forms on cda-amc.ca.
We apologize for any inconvenience and thank you for your patience.
Last Updated : August 30, 2022